Functional poly(p-phenylene)s as targeting and drug carrier materials
Source abstract
Abstract
Polymers have a substantial attention in drug delivery systems owing to the diverse intrinsic advantages. It is important to carry the drug to the target site and release to exert its effects. Herein, poly(p-phenylene)s with amino and poly(ethylene glycol) substituents (PPP-NH2-g-PEG) were used as a carrier for doxorubicin (DOX), an anticancer drug, and haloperidol, a sigma receptor targeting ligand. Both human cervix adenocarcinoma cell line (HeLa) and human keratinocyte cell line (HaCaT) having different Sigma receptor 1 (SigmaR1) expression levels were compared. HeLa was found to express twofold SigmaR1 compared to HaCaT cells. Cell imaging studies showed that, DOX cell uptake was higher in HeLa cells when targeted with haloperidol.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Pharmacological Receptor Mechanisms and Effects · Cancer therapeutics and mechanisms · Synthesis and Biological Evaluation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (53)
Show source-provided references
1. 10.1166/jnn.2015.1032510.1166/jnn.2015.10325 ↗
2. 10.1038/nrd108810.1038/nrd1088 ↗
3. 10.1021/am101196v10.1021/am101196v ↗
4. 10.1039/C5PY00780A10.1039/C5PY00780A ↗
5. 10.1016/j.ejpb.2011.08.00410.1016/j.ejpb.2011.08.004 ↗
6. 10.1016/j.ejpb.2008.11.01010.1016/j.ejpb.2008.11.010 ↗
7. 10.1039/C5RA08893C10.1039/C5RA08893C ↗
8. 10.1039/c2jm30692a10.1039/c2jm30692a ↗
9. 10.1039/C4PY00850B10.1039/C4PY00850B ↗
10. 10.1021/nn200739q10.1021/nn200739q ↗
11. 10.1039/C2CS35265F10.1039/C2CS35265F ↗
12. 10.1021/nn203165z10.1021/nn203165z ↗
13. 10.1021/bm800371n10.1021/bm800371n ↗
14. 10.1021/am406012g10.1021/am406012g ↗
15. 10.1186/1556-276X-9-24410.1186/1556-276X-9-244 ↗
16. 10.1002/anie.20046080010.1002/anie.200460800 ↗
17. 10.1021/acs.langmuir.5b0008210.1021/acs.langmuir.5b00082 ↗
18. 10.1038/sj.gt.330272110.1038/sj.gt.3302721 ↗
19. 10.1021/jm800994j10.1021/jm800994j ↗
20. 10.1002/jgm.85310.1002/jgm.853 ↗
21. 10.1021/mp100265310.1021/mp1002653 ↗
22. 10.1021/mp900316a10.1021/mp900316a ↗
23. Martin W. R. · J. Pharmacol. Exp. Ther · 1976 · 197 · 51710.1016/S0022-3565(25)30536-7 ↗
24. 10.1073/pnas.93.15.807210.1073/pnas.93.15.8072 ↗
25. 10.1369/002215541244354210.1369/0022155412443542 ↗
26. Vilner B. J. · Cancer Res · 1995 · 55 · 408
27. 10.1007/s10549-004-6590-010.1007/s10549-004-6590-0 ↗
28. Zhang Y. · Int. J. Nanomed · 2012 · 7 · 4473
29. 10.1126/science.116612710.1126/science.1166127 ↗
30. 10.1254/jjp.81.12510.1254/jjp.81.125 ↗
31. Su T. P. · J. Pharmacol. Exp. Ther · 1982 · 223 · 28410.1016/S0022-3565(25)33330-6 ↗
32. 10.1517/13543776.2013.76952210.1517/13543776.2013.769522 ↗
33. Nordenberg J. · Int. J. Oncol · 2005 · 27 · 1097
34. 10.1007/s00210-004-0961-210.1007/s00210-004-0961-2 ↗
35. 10.1016/j.progpolymsci.2004.01.00510.1016/j.progpolymsci.2004.01.005 ↗
36. 10.1021/ma050613210.1021/ma0506132 ↗
37. 10.1016/S0014-3057(01)00245-210.1016/S0014-3057(01)00245-2 ↗
38. 10.1002/pola.2197410.1002/pola.21974 ↗
39. 10.1002/pola.2762110.1002/pola.27621 ↗
40. 10.1021/bm300619310.1021/bm3006193 ↗
41. 10.1021/bm400862m10.1021/bm400862m ↗
42. 10.1016/j.canlet.2005.11.01110.1016/j.canlet.2005.11.011 ↗
43. 10.1038/cddis.2013.7910.1038/cddis.2013.79 ↗
44. 10.1006/meth.2001.126210.1006/meth.2001.1262 ↗
45. Uhlén M. · Science · 2015 · 347 · 622010.1126/science.1260419 ↗
46. 10.1016/j.bbrc.2006.04.14010.1016/j.bbrc.2006.04.140 ↗
47. Madden T. · 2003
48. Fanciulli M. · Clin. Cancer Res · 2000 · 6 · 1590
49. 10.1016/S0024-3205(00)00523-310.1016/S0024-3205(00)00523-3 ↗
50. 10.2174/13816121079356336510.2174/138161210793563365 ↗
51. 10.1017/S146114570700829210.1017/S1461145707008292 ↗
52. 10.1046/j.1471-4159.2003.01851.x10.1046/j.1471-4159.2003.01851.x ↗
53. 10.1016/j.lfs.2012.10.00210.1016/j.lfs.2012.10.002 ↗